CELSET Launches SOLTOX, a Korean Botulinum Toxin Type A Brand, for International Markets

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

CELSET-INC

More Like This

World's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence

IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position

PR Newswire associated1

Daewoong Pharmaceutical Hosts 'NABOTA Master Class'… Highlighting Safety Amid Growing Demand for High-Dose, Repetitive Treatments

PR Newswire associated0

MAYPHARM Unveils HYALMASS AQUATOX, a Next-Generation Multi-Active Skin Solution for the Global Aesthetic Market

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 2026